Biotech · Private company

Santen Inc.

Track this companyFree. Adds Santen Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials151 recruiting or active

Pipeline programs31From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline31

DE-109 44 ugPhase 3 · Uveitis; Posterior, DisorderClinicalTrials.gov · fetched Nov 12, 2026
DE-109 440 ugPhase 3 · Uveitis; Posterior, DisorderClinicalTrials.gov · fetched Nov 12, 2026
DE-109 440 μgPhase 3 · Non-Infectious Uveitis of the Posterior Segment of the EyeClinicalTrials.gov · fetched Nov 12, 2026
DE-109 880 ugPhase 3 · Uveitis; Posterior, DisorderClinicalTrials.gov · fetched Nov 12, 2026
DE-109 Intravitreal InjectionsPhase 3 · Non Infectious UveitisClinicalTrials.gov · fetched Nov 12, 2026
DE-109 Intravitreal Injections (Open Label)Phase 3 · Non Infectious UveitisClinicalTrials.gov · fetched Nov 12, 2026
DE-117 Ophthalmic SolutionPhase 3 · Primary Open-angle Glaucoma and Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
DE-117 Ophthalmic SolutionPhase 3 · Glaucoma and Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
Sham ProcedurePhase 3 · Non Infectious UveitisClinicalTrials.gov · fetched Nov 12, 2026
Timolol Maleate Ophthalmic Solution 0.5%Phase 3 · Glaucoma and Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
0.005% Latanoprost Ophthalmic SolutionPhase 2 · Open-angle Glaucoma, Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
0.1% STN1013600 ophthalmic solutionPhase 2 · PresbyopiaClinicalTrials.gov · fetched Nov 12, 2026
0.3% STN1013600 ophthalmic solutionPhase 2 · PresbyopiaClinicalTrials.gov · fetched Nov 12, 2026
0.5 mg of DE-122Phase 2 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
1.0 mg of DE-122Phase 2 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
2.0 mg DE-122 Injectable Solution + LucentisPhase 2 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
2.0 mg of DE-122Phase 2 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
4.0 mg DE-122 Injectable Solution + LucentisPhase 2 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
4.0 mg of DE-122Phase 2 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
DE-117 Ophthalmic Solution BIDPhase 2 · Primary Open-angle Glaucoma and Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
DE-117 Ophthalmic Solution QDPhase 2 · Primary Open-angle Glaucoma and Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
DE-126 Ophthalmic Solution 0.002% QDPhase 2 · Primary Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
LucentisPhase 2 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
STN1010904 ophthalmic suspension 0.03% BIDPhase 2 · Fuchs Endothelial Corneal DystrophyClinicalTrials.gov · fetched Nov 12, 2026
STN1010904 ophthalmic suspension 0.1% BIDPhase 2 · Fuchs Endothelial Corneal DystrophyClinicalTrials.gov · fetched Nov 12, 2026
Timolol Maleate Ophthalmic Solution 0.5% BIDPhase 2 · Primary Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
Topical high dose of DE-126 Ophthalmic SolutionPhase 2 · Open-angle Glaucoma, Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
Topical low dose of DE-126 Ophthalmic SolutionPhase 2 · Open-angle Glaucoma, Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
Topical medium dose of DE-126 Ophthalmic SolutionPhase 2 · Open-angle Glaucoma, Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
Topical ultra-low dose of DE-126 Ophthalmic SolutionPhase 2 · Open-angle Glaucoma, Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic SolutionPhase 2 · Open-angle Glaucoma, Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials15

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With PresbyopiaPHASE2 · COMPLETED · started Dec 22, 2022ClinicalTrials.gov NCT05665387 · fetched Nov 12, 2026
Intravitreal Sirolimus as Therapeutic Approach to UveitisPHASE2 · WITHDRAWN · started Sep 1, 2022ClinicalTrials.gov NCT01280669 · fetched Nov 12, 2026
A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)PHASE2 · COMPLETED · started May 19, 2022ClinicalTrials.gov NCT05376176 · fetched Nov 12, 2026
Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionPHASE2 · COMPLETED · started Dec 17, 2020ClinicalTrials.gov NCT04742283 · fetched Nov 12, 2026
Imaging Quantification of Inflammation (IQI)ACTIVE_NOT_RECRUITING · started Sep 22, 2019ClinicalTrials.gov NCT04704609 · fetched Nov 12, 2026
Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6PHASE2 · COMPLETED · started Jan 28, 2019ClinicalTrials.gov NCT03858894 · fetched Nov 12, 2026
LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the EyePHASE3 · TERMINATED · started Nov 19, 2018ClinicalTrials.gov NCT03711929 · fetched Nov 12, 2026
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 StudyPHASE3 · COMPLETED · started Sep 27, 2018ClinicalTrials.gov NCT03691662 · fetched Nov 12, 2026
DE-117 Spectrum 5 StudyPHASE3 · COMPLETED · started Sep 27, 2018ClinicalTrials.gov NCT03697811 · fetched Nov 12, 2026
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 StudyPHASE3 · COMPLETED · started Sep 14, 2018ClinicalTrials.gov NCT03691649 · fetched Nov 12, 2026
A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel StudyPHASE2 · COMPLETED · started Jul 25, 2017ClinicalTrials.gov NCT03216902 · fetched Nov 12, 2026
Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration SubjectsPHASE2 · COMPLETED · started Jul 5, 2017ClinicalTrials.gov NCT03211234 · fetched Nov 12, 2026
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular DegenerationPHASE1_PHASE2 · COMPLETED · started Sep 16, 2015ClinicalTrials.gov NCT02555306 · fetched Nov 12, 2026
A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development ProgramPHASE3 · COMPLETED · started Sep 29, 2014ClinicalTrials.gov NCT02251938 · fetched Nov 12, 2026
Study Assessing Double-masked Uveitis TreatmentPHASE3 · COMPLETED · started May 1, 2011ClinicalTrials.gov NCT01358266 · fetched Nov 12, 2026